A federal review board voted Thursday to open up rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is non-binding. The FDA has given no indication on whether it will adopt the suggestion. The move came after weeks of community hearings. Wellness backers lobbied intensely for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could redefine how the agency handles a part of the wellness market that is growing very fast. Patient groups are waiting to see if the FDA picks up the plan. A spokesperson offered no set date for a reaction. Industry voices argue the change would broaden access to substances some say help. Opponents warn that looser rules could invite misuse across a wide-open market. The Thursday vote only plants the seed for a shift, and the final say rests with the federal regulator.